Posted by Michael Wonder on 02 Jul 2024
ICER publishes evidence report on treatment for anaemia in myelodysplastic syndrome
2 July 2024 - There are significant uncertainties regarding long term efficacy and safety of imetelstat; treatment would achieve common thresholds for cost effectiveness if priced between $94,800 - $113,000/year.
The ICER today posted its revised evidence report assessing the comparative clinical effectiveness and value of imetelstat (Rytelo, Geron Corporation) for the treatment of anaemia in myelodysplastic syndrome.
